Aspirin reduces risk of developing diabetes

Not sure if my readers have noticed it, but Big Pharma has drastically increased their bashing of aspirin since the pandemic started. Those attacks began when a few studies published back in 2020 demonstrated that aspirin users had a much lower risk of both contracting and dying from COVID-19, and that aspirin was unique among NSAID in providing such benefits. The bashing of aspirin continues even in the study below, but it is forced to (begrudgingly) admit that low-dose aspirin led to 15% lower risk of developing diabetes in older adults. Now, 15% reduction may not seem like much, but so far there has been no other drug shown to lower risk of developing diabetes. Also, these effects were seen from low-dose aspirin and the pro-metabolic effects of aspirin are known to be dose-dependent (e.g. uncoupling and inhibition of both lipolysis / fatty acid oxidation), so higher doses would have likely led to much bigger risk reduction. Of course, the fear-mongering from Big Pharma about aspirin’s dire bleeding risks effectively prevents human trials with higher doses, so unfortunately aspirin probably won’t see much clinical use as prevention/therapy for diabetes.

“…A total of 16,209 participants were included in the analysis (8,086 randomized to aspirin and 8,123 to placebo). Over a median follow-up of 4.7 years, 995 incident diabetes cases were recorded (aspirin: 459, placebo: 536). Compared with placebo, the aspirin group had a 15% reduction in incident diabetes and a slower rate of increase in FPG (difference in annual FPG change: -0.006 mmol/L). The authors say, “Aspirin treatment reduced incident diabetes and slowed the increase in fasting plasma glucose over time among initially healthy older adults. Given the increasing prevalence of type 2 diabetes among older adults, the potential for anti-inflammatory agents like aspirin to prevent type 2  or improve glucose levels needs further study.””

Author: haidut